Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RIP Jerry Viverito aka The Paper Chaser
RIP brotha!!! You were a friend, my 1st roommate, a business partner, a brother... I will miss you JV... I'm gonna head out that way in the next month or so to meet your daughter... Don't worry partner I've got eyes on ur fam now... til we meet again - Rest in Paradise buddy
Small-Cap Companies Providing Next Generation Solutions: http://finance.yahoo.com/news/small-cap-companies-providing-next-111500966.html
Good Morning Traders!!! $IOGA on Alert this morning!!! Dont miss out!!! Small-Cap Companies Providing Next Generation Solutions: http://finance.yahoo.com/news/small-cap-companies-providing-next-111500966.html
Good Morning Traders!!! $IOGA on Alert this morning!!! Dont miss out!!! Small-Cap Companies Providing Next Generation Solutions: http://finance.yahoo.com/news/small-cap-companies-providing-next-111500966.html
$PLPL On Alert!!!
$PLPL On Alert!!!
Dont miss out on $PLPL!!!
Dont miss out on $PLPL!!!
$PLPL on Alert this AM!!!
$PLPL on Alert this AM!!!
I also have $NVLX on alert this morning... Last week they announced Nuvilex, Inc. Designing Protocol for Its Next Pancreatic Cancer Trial http://finance.yahoo.com/news/nuvilex-inc-designing-protocol-next-133000877.html as well as Nuvilex: the Quintessential Mid-Late Stage Biotech Opportunity http://finance.yahoo.com/news/nuvilex-quintessential-mid-stage-biotech-133000937.html - Keep on your radar and pick up a starter if you have yet to do so - cant wait to see whats next with this international biotechnology firm!!!
ready for a big week
Morning bud
Keeping an eye on this 1
$NVLX on alert this morning... Last week they announced Nuvilex, Inc. Designing Protocol for Its Next Pancreatic Cancer Trial http://finance.yahoo.com/news/nuvilex-inc-designing-protocol-next-133000877.html as well as Nuvilex: the Quintessential Mid-Late Stage Biotech Opportunity http://finance.yahoo.com/news/nuvilex-quintessential-mid-stage-biotech-133000937.html - Keep on your radar and pick up a starter if you have yet to do so - cant wait to see whats next with this international biotechnology firm!!!
$NVLX on alert this morning... Last week they announced Nuvilex, Inc. Designing Protocol for Its Next Pancreatic Cancer Trial http://finance.yahoo.com/news/nuvilex-inc-designing-protocol-next-133000877.html as well as Nuvilex: the Quintessential Mid-Late Stage Biotech Opportunity http://finance.yahoo.com/news/nuvilex-quintessential-mid-stage-biotech-133000937.html - Keep on your radar and pick up a starter if you have yet to do so - cant wait to see whats next with this international biotechnology firm!!!
$NVLX on the Radar!!! Keep your eyes on and dont miss out!!!
Good evening guys
$NVLX on the Radar!!! Keep your eyes on and dont miss out!!!
$VDSC $FGLD $SAPX all on Radar!!!
$VDSC $FGLD $SAPX all on Radar!!!
$VDSC $INOL $TENP Tuesday Trifecta!!!
$VDSC $INOL $TENP Tuesday Trifecta!!!
$VDSC $NVLX $AEGA (sleeper play)
$VDSC $NVLX $AEGA (sleeper play)
$VDSC Update shareholders for New Developements
http://ih.advfn.com/p.php?pid=nmona&article=58983419&symbol=VDSC
$VDSC Update shareholders for New Developements
http://ih.advfn.com/p.php?pid=nmona&article=58983419&symbol=VDSC
$STBV +20% $VDSC vol there looking for pop...
$STBV +20% $VDSC vol there looking for pop...
$VDSC $ESIV $GRLT - Tuesday Trifecta!!!
$VDSC $ESIV $GRLT - Tuesday Trifecta!!!
$VDSC $IOGA $GRPR Thursday Trifecta!!!
$VDSC $IOGA $GRPR Thursday Trifecta!!!
$OMVS News OMVS Lines Up New Acquisition Targets in $300 Billion Online Transportation Industry
TAMPA, Fla.--(BUSINESS WIRE)--
After formally announcing its revolutionary new business model to capture a share of the booming $300 billion online transportation sector, On the Move Systems Corp. (OMVS) is wasting no time in lining up emerging transportation providers for potential partnership and acquisition.
The company has already initiated talks with private air carriers, ground transportation services and intermodal and logistics providers well-positioned to help OMVS achieve its mission to create a next-generation online transportation portal. Competing portals such as Kayak, Expedia, Travelocity, Orbitz and more have revolutionized the way we move from place to place, and OMVS is currently exploring new opportunities to foster a similar revolution for people and businesses looking to avoid the big airlines and shipping companies without paying exorbitant fees.
“The online transportation segment has been forecast by many experts to represent almost a third of the trillion-dollar global transportation market,” said OMVS CEO Patrick Brown. “The evolution of this industry is far from over, and we believe we have the technology to push this sector into a new era of customer service.”
By offering easy, round-the-clock access to niche service providers, OMVS plans to market new technology solutions that will allow it to compete in the online transportation market alongside Priceline.com (PCLN), TripAdvisor.com (TRIP) and Expedia.com (EXPE).
For more information on On the Move Systems’ bold new direction, please visit www.onthemovesystems.com.
About On the Move Systems, Inc.
On the Move Systems, Inc. (OTCBB: OMVS) is focused on the development of cutting-edge technology across a broad spectrum of industries. The company is currently exploring new online tools to reduce costs and increase convenience in the tourism and transportation industry. For more information, please visit our website at www.onthemovesystems.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
On the Move Systems, Inc.
Patrick Brown, 813-367-9511
President and CEO
info@onthemovesystems.com
$OMVS News OMVS Lines Up New Acquisition Targets in $300 Billion Online Transportation Industry
TAMPA, Fla.--(BUSINESS WIRE)--
After formally announcing its revolutionary new business model to capture a share of the booming $300 billion online transportation sector, On the Move Systems Corp. (OMVS) is wasting no time in lining up emerging transportation providers for potential partnership and acquisition.
The company has already initiated talks with private air carriers, ground transportation services and intermodal and logistics providers well-positioned to help OMVS achieve its mission to create a next-generation online transportation portal. Competing portals such as Kayak, Expedia, Travelocity, Orbitz and more have revolutionized the way we move from place to place, and OMVS is currently exploring new opportunities to foster a similar revolution for people and businesses looking to avoid the big airlines and shipping companies without paying exorbitant fees.
“The online transportation segment has been forecast by many experts to represent almost a third of the trillion-dollar global transportation market,” said OMVS CEO Patrick Brown. “The evolution of this industry is far from over, and we believe we have the technology to push this sector into a new era of customer service.”
By offering easy, round-the-clock access to niche service providers, OMVS plans to market new technology solutions that will allow it to compete in the online transportation market alongside Priceline.com (PCLN), TripAdvisor.com (TRIP) and Expedia.com (EXPE).
For more information on On the Move Systems’ bold new direction, please visit www.onthemovesystems.com.
About On the Move Systems, Inc.
On the Move Systems, Inc. (OTCBB: OMVS) is focused on the development of cutting-edge technology across a broad spectrum of industries. The company is currently exploring new online tools to reduce costs and increase convenience in the tourism and transportation industry. For more information, please visit our website at www.onthemovesystems.com.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Contact:
On the Move Systems, Inc.
Patrick Brown, 813-367-9511
President and CEO
info@onthemovesystems.com
$PLPL News European Study Confirms Anti-Malarial Effect of Green Tea Extract
BALTIMORE, MD--(Marketwired - Aug 20, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a research study published by a number of scientists in Italy demonstrates that green tea extracts do have a positive impact in treating malaria, in vitro. While this study predates the recent Plandaí Biotechnology, Inc. (OTCQB: PLPL) malaria study, it nonetheless supports the Company's series of tests to date that green tea extracts demonstrate an antimalarial effect.
In the Italy-based study, the scientists found that "...a crude extract of green tea as well as two of its main constituents, epigallocatechin-3-gallate (EGCG) and epicatechin gallate (ECG), strongly inhibit Plasmodium falciparum growth in vitro. Both these catechins are found to potentiate the antimalarial effects of artemisinin (a key malaria treatment) without interfering with the folate pathway." Moreover, the tests showed that the combination of artemisinin and the green tea catechins displayed a strong combined effect.
Interestingly, while in previous studies Plandaí confirmed the same effect, in its most recent tests, the Company recently announced incredible results from its second round of in vitro testing of Phytofare™ Catechin Complex, used to kill the malaria parasite plasmodium falciparum. The results of this independent investigation confirmed a twelve-times greater efficacy in killing the parasite. It should be noted that in this round the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies.
Since malaria is not a disease that affects people in most Western nations, many people are unaware of the reach of this deadly disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. As a result, success in developing a highly effective commercial botanical extract to treat malaria is a very lucrative and therapeutic opportunity for Plandaí.
To that end, management plans to complete a commercial delivery system by encapsulating Phytofare™ Catechin Complex into a proprietary nano-delivery system that is expected to deliver improved absorption and protection against gut metabolization, allowing the Phytofare™ to remain protected and intact until it reaches the bloodstream.
In addition, further independent scientific investigations of Phytofare™ Catechin Complex, combined with arteseminin which has also been processed into a Phytofare™ extract, will be undertaken both in vitro and in mouse models to validate the extract for oral consumption as an antimalarial drug target. Pending favorable results, the company will seek approval to commence a Phase II human clinical trial.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com
$PLPL News European Study Confirms Anti-Malarial Effect of Green Tea Extract
BALTIMORE, MD--(Marketwired - Aug 20, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that a research study published by a number of scientists in Italy demonstrates that green tea extracts do have a positive impact in treating malaria, in vitro. While this study predates the recent Plandaí Biotechnology, Inc. (OTCQB: PLPL) malaria study, it nonetheless supports the Company's series of tests to date that green tea extracts demonstrate an antimalarial effect.
In the Italy-based study, the scientists found that "...a crude extract of green tea as well as two of its main constituents, epigallocatechin-3-gallate (EGCG) and epicatechin gallate (ECG), strongly inhibit Plasmodium falciparum growth in vitro. Both these catechins are found to potentiate the antimalarial effects of artemisinin (a key malaria treatment) without interfering with the folate pathway." Moreover, the tests showed that the combination of artemisinin and the green tea catechins displayed a strong combined effect.
Interestingly, while in previous studies Plandaí confirmed the same effect, in its most recent tests, the Company recently announced incredible results from its second round of in vitro testing of Phytofare™ Catechin Complex, used to kill the malaria parasite plasmodium falciparum. The results of this independent investigation confirmed a twelve-times greater efficacy in killing the parasite. It should be noted that in this round the Company elected to use the complete Phytofare™ complex and not just the isolated EGCG (Epigallocatechin Gallate) catechin used in earlier studies.
Since malaria is not a disease that affects people in most Western nations, many people are unaware of the reach of this deadly disease which potentially impacts hundreds of millions of people and kills 600,000 in the African continent alone. As a result, success in developing a highly effective commercial botanical extract to treat malaria is a very lucrative and therapeutic opportunity for Plandaí.
To that end, management plans to complete a commercial delivery system by encapsulating Phytofare™ Catechin Complex into a proprietary nano-delivery system that is expected to deliver improved absorption and protection against gut metabolization, allowing the Phytofare™ to remain protected and intact until it reaches the bloodstream.
In addition, further independent scientific investigations of Phytofare™ Catechin Complex, combined with arteseminin which has also been processed into a Phytofare™ extract, will be undertaken both in vitro and in mouse models to validate the extract for oral consumption as an antimalarial drug target. Pending favorable results, the company will seek approval to commence a Phase II human clinical trial.
Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com